The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

 
Web www.patentalert.com

< Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus

> Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant

> Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
~ 00540